Furthermore, anti-VEGF therapy is more effective for nonischemic CRVO than ischemic CRVO [20], and even CRVO with mild retinal ischemia can result in relatively high VEGF levels [18]. The gene discussed is VEGFA; the disease is retinal ischemia.